Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRCA2 oncogenic variants status confers therapeutic sensitivity to Olaparib in patients with Prostate Adenocarcinoma.
This statement is based on a regulatory approval from the Health Canada:
LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM mutated metastatic castrationresistant Prostate Cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent. BRCA or ATM mutations must be confirmed before LYNPARZA treatment is initiated.